126 related articles for article (PubMed ID: 36914601)
1. Impact of an opioid use disorder consult service on hospitalized trauma patients with opioid use disorder.
Muller M; Weyer G; Zakrison T; Ari M
J Trauma Acute Care Surg; 2023 Aug; 95(2):226-233. PubMed ID: 36914601
[TBL] [Abstract][Full Text] [Related]
2. A Model to Improve Care and Enhance the Physician-Patient Relationship for Hospitalized Patients With Opioid Use Disorder.
Ari M; Murray J; Dickson S; Kerins A; Weyer G
Acad Med; 2023 Jun; 98(6S):S25-S27. PubMed ID: 36811966
[TBL] [Abstract][Full Text] [Related]
3. Overcoming challenges in acute care hospitalizations for patients with opioid use disorder.
Kerins A; Ito S; Ari M; Murray JP; Weyer G
J Am Pharm Assoc (2003); 2023; 63(1):204-211.e2. PubMed ID: 36115762
[TBL] [Abstract][Full Text] [Related]
4. Effect of a Co-Located Bridging Recovery Initiative on Hospital Length of Stay Among Patients With Opioid Use Disorder: The BRIDGE Randomized Clinical Trial.
Marcovitz D; Dear ML; Donald R; Edwards DA; Kast KA; Le TDV; Shah MV; Ferrell J; Gatto C; Hennessy C; Buie R; Rice TW; Sullivan W; White KD; Van Winkle G; Wolf R; Lindsell CJ;
JAMA Netw Open; 2024 Feb; 7(2):e2356430. PubMed ID: 38411964
[TBL] [Abstract][Full Text] [Related]
5. Successful engagement in buprenorphine treatment among hospitalized patients with opioid use disorder and trauma.
Bhatraju EP; Ludwig-Barron N; Takagi-Stewart J; Sandhu HK; Klein JW; Tsui JI
Drug Alcohol Depend; 2020 Oct; 215():108253. PubMed ID: 32890919
[TBL] [Abstract][Full Text] [Related]
6. Impact of a pharmacist-led substance use disorder transitions of care clinic on postdischarge medication treatment retention.
Smith A; Hansen J; Colvard M
J Subst Abuse Treat; 2021 Nov; 130():108440. PubMed ID: 34118708
[TBL] [Abstract][Full Text] [Related]
7. Predictors of Opioid and Alcohol Pharmacotherapy Initiation at Hospital Discharge Among Patients Seen by an Inpatient Addiction Consult Service.
Englander H; King C; Nicolaidis C; Collins D; Patten A; Gregg J; Korthuis PT
J Addict Med; 2020; 14(5):415-422. PubMed ID: 31868830
[TBL] [Abstract][Full Text] [Related]
8. Discharge locations after hospitalizations involving opioid use disorder among medicare beneficiaries.
Moyo P; Eliot M; Shah A; Goodyear K; Jutkowitz E; Thomas K; Zullo AR
Addict Sci Clin Pract; 2022 Oct; 17(1):57. PubMed ID: 36209151
[TBL] [Abstract][Full Text] [Related]
9. Study protocol for a pragmatic trial of the Consult for Addiction Treatment and Care in Hospitals (CATCH) model for engaging patients in opioid use disorder treatment.
McNeely J; Troxel AB; Kunins HV; Shelley D; Lee JD; Walley A; Weinstein ZM; Billings J; Davis NJ; Marcello RK; Schackman BR; Barron C; Bergmann L
Addict Sci Clin Pract; 2019 Feb; 14(1):5. PubMed ID: 30777122
[TBL] [Abstract][Full Text] [Related]
10. The Substance Use Treatment and Recovery Team (START) study: protocol for a multi-site randomized controlled trial evaluating an intervention to improve initiation of medication and linkage to post-discharge care for hospitalized patients with opioid use disorder.
Ober AJ; Murray-Krezan C; Page K; Friedmann PD; Chan Osilla K; Ryzewicz S; Huerta S; Mazer MW; Leamon I; Messineo G; Watkins KE; Nuckols T; Danovitch I
Addict Sci Clin Pract; 2022 Jul; 17(1):39. PubMed ID: 35902888
[TBL] [Abstract][Full Text] [Related]
11. Interventions for hospitalized medical and surgical patients with opioid use disorder: A systematic review.
French R; Aronowitz SV; Brooks Carthon JM; Schmidt HD; Compton P
Subst Abus; 2022; 43(1):495-507. PubMed ID: 34283698
[No Abstract] [Full Text] [Related]
12. Associations Between Inpatient Induction on Medications for Opioid Use Disorder and Postdischarge Medications for Opioid Use Disorder Adherence, Overdose, and Service Use.
Noam KR; Schmutte TJ; Pirard S; Bourdon C; Langless D; Plant R
J Addict Med; 2023 May-Jun 01; 17(3):e199-e201. PubMed ID: 37267183
[TBL] [Abstract][Full Text] [Related]
13. Inpatient Opioid Use Disorder Treatment by Generalists is Associated With Linkage to Opioid Treatment Programs After Discharge.
Tierney HR; Rowe CL; Coffa DA; Sarnaik S; Coffin PO; Snyder HR
J Addict Med; 2022 Mar-Apr 01; 16(2):169-176. PubMed ID: 33813579
[TBL] [Abstract][Full Text] [Related]
14. Pilot randomized controlled trial of a hospital-based substance use treatment and recovery team (START) to improve initiation of medication for alcohol or opioid use disorder and linkage to follow-up care.
Ober AJ; Osilla KC; Klein DJ; Burgette LF; Leamon I; Mazer MW; Messineo G; Collier S; Korouri S; Watkins KE; Ishak W; Nuckols T; Danovitch I
J Subst Use Addict Treat; 2023 Jul; 150():209063. PubMed ID: 37156424
[TBL] [Abstract][Full Text] [Related]
15. Rural-urban disparities in the availability of hospital-based screening, medications for opioid use disorder, and addiction consult services.
Franz B; Cronin CE; Lindenfeld Z; Pagan JA; Lai AY; Krawczyk N; Rivera BD; Chang JE
J Subst Use Addict Treat; 2024 May; 160():209280. PubMed ID: 38142042
[TBL] [Abstract][Full Text] [Related]
16. Implementation of a comprehensive hospitalist-led initiative to improve care for patients with opioid use disorder.
Clifton D; Ivey N; Poley S; O'Regan A; Raman SR; Frascino N; Hamilton S; Setji N
J Hosp Med; 2022 Jun; 17(6):427-436. PubMed ID: 35535562
[TBL] [Abstract][Full Text] [Related]
17. Simulating the impact of Addiction Consult Services in the context of drug supply contamination, hospitalizations, and drug-related mortality.
King CA; Cook R; Wheelock H; Korthuis PT; Leahy JM; Goff A; Morris CD; Englander H
Int J Drug Policy; 2022 Feb; 100():103525. PubMed ID: 34837879
[TBL] [Abstract][Full Text] [Related]
18. Undertreatment of opioid use disorder in patients hospitalized with injection drug use-associated infections.
Rosenthal ES; Brokus C; Sun J; Carpenter JE; Catalanotti J; Eaton EF; Steck AR; Kuo I; Burkholder GA; Akselrod H; McGonigle K; Moran T; Mai W; Notis M; Del Rio C; Greenberg A; Saag MS; Kottilil S; Masur H; Kattakuzhy S
AIDS; 2023 Oct; 37(12):1799-1809. PubMed ID: 37352497
[TBL] [Abstract][Full Text] [Related]
19. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.
Morgan JR; Schackman BR; Leff JA; Linas BP; Walley AY
J Subst Abuse Treat; 2018 Feb; 85():90-96. PubMed ID: 28733097
[TBL] [Abstract][Full Text] [Related]
20. OUD MEETS: A novel program to increase initiation of medications for opioid use disorder and improve outcomes for hospitalized patients being discharged to skilled nursing facilities.
Tassey TE; Ott GE; Alvanzo AAH; Peirce JM; Antoine D; Buresh ME
J Subst Abuse Treat; 2022 Dec; 143():108895. PubMed ID: 36215913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
